Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin
Abstract
Abstract: Although selective SGLT2 inhibitors improve heart failure (HF) outcomes, they do not consistently reduce atherothrombotic events (myocardial infarctions and strokes). Clinical trials with sotagliflozin, the first dual SGLT1/2 inhibitor, have shown significant reductions in both HF outcomes and atherothrombotic events: an effect not seen with highly selective SGLT2 inhibitors such as empagliflozin. This effect may be related to SGLT1 inhibition, because SGLT1 is widely expressed in the myocardium, platelets, and endothelial cells, suggesting a potential antithrombotic mechanism. The SOTA-THROMBOSIS trial is a randomized, cross-over study in healthy volunteers (n = 16) comparing the antithrombotic effects of dual SGLT1/2 inhibition with sotagliflozin and selective SGLT2 inhibition with empagliflozin. All participants will receive each treatment for 4 weeks, separated by a 1-month washout. Blood thrombogenicity under high and low shear rate conditions will be assessed using the Badimon perfusion chamber. Additional assessments include platelet aggregation (Multiplate Analyzer) and clot formation kinetics using thromboelastometry (RoTEM). Measurements will be performed at baseline (pretreatment) and at the end of each treatment period. The cross-over design-where each participant receives both study treatments and serves as his/her own control-significantly reduces both, intrasubject and intragroup variability. We hypothesize that both treatments will reduce blood…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 16 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.